BiondVax Pharmaceuticals Ltd. announced earnings results for the third quarter ended September 30, 2020. For the third quarter, the company announced operating income was ILS 55.603 million compared to operating loss of ILS 18.923 million a year ago. Net income was ILS 55.315 million compared to net loss of ILS 19.355 million a year ago. Basic earnings per share from continuing operations was ILS 0.12 compared to basic loss per share from continuing operations of ILS 0.05 a year ago. Diluted earnings per share from continuing operations was ILS 0.1 compared to diluted loss per share from continuing operations of ILS 0.05 a year ago. For the nine months, operating income was ILS 19.467 million compared to operating loss of ILS 45.778 million a year ago. Net income was ILS 9.642 million compared to net loss of ILS 66.178 million a year ago. Basic earnings per share from continuing operations was ILS 0.02 compared to basic loss per share from continuing operations of ILS 0.23 a year ago.